- Home
- NCL vs CYCC Comparison
NCL vs CYCC Comparison
Compare NCL & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- CYCC
- Stock Information
- Founded
- NCL 2013
- CYCC 1992
- Country
- NCL United States
- CYCC Malaysia
- Employees
- NCL N/A
- CYCC N/A
- Industry
- NCL
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- NCL
- CYCC Health Care
- Exchange
- NCL Nasdaq
- CYCC Nasdaq
- Market Cap
- NCL 15.1M
- CYCC 17.5M
- IPO Year
- NCL 2023
- CYCC N/A
- Fundamental
- Price
- NCL $0.15
- CYCC $7.12
- Analyst Decision
- NCL
- CYCC
- Analyst Count
- NCL 0
- CYCC 0
- Target Price
- NCL N/A
- CYCC N/A
- AVG Volume (30 Days)
- NCL 1.8M
- CYCC 86.9K
- Earning Date
- NCL 08-19-2025
- CYCC 08-13-2025
- Dividend Yield
- NCL N/A
- CYCC N/A
- EPS Growth
- NCL N/A
- CYCC N/A
- EPS
- NCL N/A
- CYCC N/A
- Revenue
- NCL $12,009,378.00
- CYCC $10,000.00
- Revenue This Year
- NCL N/A
- CYCC $137.21
- Revenue Next Year
- NCL N/A
- CYCC N/A
- P/E Ratio
- NCL N/A
- CYCC N/A
- Revenue Growth
- NCL N/A
- CYCC N/A
- 52 Week Low
- NCL $0.13
- CYCC $3.08
- 52 Week High
- NCL $1.52
- CYCC $597.60
- Technical
- Relative Strength Index (RSI)
- NCL 43.14
- CYCC 41.06
- Support Level
- NCL $0.14
- CYCC $7.30
- Resistance Level
- NCL $0.16
- CYCC $8.82
- Average True Range (ATR)
- NCL 0.01
- CYCC 0.63
- MACD
- NCL 0.00
- CYCC 0.03
- Stochastic Oscillator
- NCL 50.88
- CYCC 17.87
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.